Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial

Recombinant human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibody JS016 showed neutralizing and therapeutic effects in preclinical studies. The clinical efficacy and safety of the therapy needed to be evaluated. In this phase 2/3, multicenter, randomized, open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Run, Jiang, Li, Yang, Ting, Wang, Changsong, Zhang, Yi, Chen, Xu, Xie, Jianfeng, Guo, Yuanbin, Weng, Li, Kang, Yan, Yu, Kaijiang, Qiu, Haibo, Du, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923168/
https://www.ncbi.nlm.nih.gov/pubmed/35191746
http://dx.doi.org/10.1128/aac.02045-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923168/
https://www.ncbi.nlm.nih.gov/pubmed/35191746
http://dx.doi.org/10.1128/aac.02045-21

Ejemplares similares